When people develop myelodysplastic neoplasms (MDS), the healthy maturation of blood cells is impaired. Severe forms, known as higher-risk MDS, are characterized by rapid progression, severe symptoms and often a transition to acute leukemia. Patients for whom potentially curative or intensive treatments, such as stem cell transplantation or high-dose chemotherapy, are not suitable, have very few alternative treatment options.